Justin T Matulay
Overview
Explore the profile of Justin T Matulay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holland A, Wilson H, Gambill B, Lorenz W, Salvino M, Rose M, et al.
Ann Surg Oncol
. 2024 Jul;
31(12):8394-8404.
PMID: 39080130
Introduction: Prostate cancer (PCa) is the most diagnosed noncutaneous malignancy and second leading-cause of cancer death in men, yet screening is decreasing. As PCa screening has become controversial, socioeconomic disparities...
2.
Lim A, Westerman M, Korokovic A, Matulay J, Narayan V, Navai N
Bladder Cancer
. 2024 Jul;
8(2):193-209.
PMID: 38993364
Background: The benefit of surgery of the primary tumor in metastatic bladder cancer is unknown. Objective: Perform a comprehensive contemporary literature review on the benefit of surgery of the primary...
3.
Kamat A, Lobo N, Lerner S, Li R, Matulay J, Palou J, et al.
Bladder Cancer
. 2024 Jul;
8(2):113-117.
PMID: 38993360
When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2)...
4.
Sinks A, Holck H, McGrath L, Zeng L, Gaston K, Riggs S, et al.
Urol Pract
. 2024 Jun;
11(4):736-744.
PMID: 38899655
Introduction: Previous literature suggests socioeconomic status and racial disparities impact management decisions for patients with small renal masses. We aim to build upon these findings and examine how these modalities...
5.
Sinks A, Holck H, McGrath L, Zeng L, Gaston K, Riggs S, et al.
Urol Pract
. 2024 Jun;
11(4):744.
PMID: 38899648
No abstract available.
6.
Ivan S, Roebuck E, Sinks A, Robinson M, Clark P, Gaston K, et al.
Urol Oncol
. 2024 May;
42(10):332.e1-332.e9.
PMID: 38735799
Introduction: The effect of individual non-narcotic analgesics in cystectomy enhanced recovery after surgery (ERAS) is unknown. Additionally, many non-narcotic medications are associated with side effects pertinent to the cystectomy population....
7.
Ivan S, Holck H, Robinson M, Shea R, Wallander M, Parker B, et al.
Urol Oncol
. 2023 Jul;
41(10):432.e1-432.e9.
PMID: 37455232
Objectives: Opioid use, misuse, and diversion is of paramount concern in the United States. Radical cystectomy is typically managed with some component of opioid pain control. We evaluated persistent opioid...
8.
9.
Burgess E, Livasy C, Symanowski J, Matulay J, Grigg C, Clark P, et al.
Urol Oncol
. 2023 Jun;
41(8):357.e23-357.e29.
PMID: 37295980
Objectives: Novel regimens targeting immune checkpoints and the cMET or HER2 pathways are under investigation in metastatic urothelial carcinoma (mUC) though co-expression of these molecular targets has not been defined....
10.
Kearns J, Matulay J, Anderson W, Hetherington T, Grigg C, Zhu J, et al.
Urol Pract
. 2023 May;
8(6):619-623.
PMID: 37145508
Introduction: 5-Alpha reductase inhibitor (5-ARI) use leads to a 50% decline in serum prostate specific antigen (PSA) without a concomitant decrease in prostate cancer (PCa) risk. We hypothesize that failure...